International

Moderna Covid-19 less effective against Omicron

Drugmaker Moderna's CEO set off fresh alarm bells in financial markets on Tuesday after he warned that COVID-19 vaccines were unlikely to be as effective against the Omicron variant as they have been against the Delta version.

Crude oil futures shed more than a dollar, the Australian currency hit a year low, and Nikkei gave up gains as Stéphane Bancel's comments spurred fears that vaccine resistance could lead to more sickness and hospitalisations, prolonging the pandemic.

"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta," Moderna CEO Bancel told the Financial Times in an interview.

"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to . . . are like 'this is not going to be good'," Bancel said.

Moderna did not reply to a Reuters' request for comment on the interview and on when it expects to have data on the effectiveness of its vaccine against Omicron, which the World Health Organization (WHO) says carries a "very high" risk of infection surges.

Bancel had earlier said on CNBC that there should be more clarity on the efficacy of COVID-19 vaccines against Omicron in about two weeks, and that it could take months to begin shipping a vaccine that work against the new variant.

The WHO and scientists have also said it could take days to several weeks to understand the level of severity of the variant and its potential to escape protection against immunity induced by vaccines.

Source: Reuters